【结 构 式】 |
【分子编号】67767 【品名】(E)-ethyl 3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylate 【CA登记号】 |
【 分 子 式 】C36H37BrN6O3 【 分 子 量 】681.632 【元素组成】C 63.44% H 5.47% Br 11.72% N 12.33% O 7.04% |
合成路线1
该中间体在本合成路线中的序号:(IVc)Chlorination of carboxylic acid (I) with SOCl2 in the presence of NMP in THF/toluene, followed by condensation of the resulting acid chloride with the amine HCl (II) or its free base using DIEA in THF, provides the carboxamide (IVa) . Alternatively, condensation of carboxylic acid (I) with the amino esters (IIIa) or (IIIb) by means of HATU and Et3N or DIEA in DMSO affords the corresponding carboxamides (IVb) or (IVc) . Finally, butyl (IVa) ,methyl (IVb) or ethyl (IVc) esters are hydrolyzed with aqueous NaOH in THF/MeOH at 67 °C or DMSO , and then treated with aqueous NaOH in THF .
【1】 Boecher, W., Haefner, C., Kukolj, G. (Boehringer Ingelheim Pharma GmbH & Co. KG). Combination therapy for treating HCV infection. CN 103228278, EP 2621495, JP 2013540112, KR 2013116245, US 2012135949, WO 2012041771. |
【2】 Brickl, R.-S., Chen, S., Chung, J. et al. (Boehringer Ingelheim Pharma GmbH & Co. KG). Solid state forms of a potent HCV inhibitor. CN 103153987, EP 2621921, JP 2013543495, KR 2013108326, US 2012122887, US 8598183, US 2014057928, WO 2012044520. 3. Mensa, F., Nehmiz, G. (Boehringer Ingelheim Pharma GmbH & Co. KG). Oral combination therapy for treating HCV infection in specific patient subgenotype populations. WO 2013147749. |
【3】 Mensa, F. (Boehringer Ingelheim Pharma GmbH & Co. KG). Oral combination therapy for treating HCV infection in specific patient sub-population. WO 2013147750. |
【4】 LaPlante, S.R., Boes, M., Brochu, C. et al. Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors. Discovery of deleobuvir (BI 207127). J Med Chem 2014, 57(5): 1845-54. |
【5】 Mensa, F., Nehmiz, G. (Boehringer Ingelheim Pharma GmbH & Co. KG). Oral combination therapy for treating HCV infection in specific patient subgenotype populations. WO 2013147749. |
【6】 Tsantrizos, Y.S., Chabot, C., Beaulieu, P. et al. (Boehringer Ingelheim Pharma GmbH & Co. KG). Viral polymerase inhibitors. CN 102911161, CN 103304541, CN 103319464, CN 103333162, EP 1718608, EP 2626354, JP 2007523094, JP 2010195818, JP 2010280740, KR 2012091276, US 2005222236, US 8030309, WO 2005080388. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(IIIa) | 67765 | (E)-methyl 3-(2-(1-aminocyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylate | C16H19N3O2 | 详情 | 详情 | |
(IIIb) | 67766 | (E)-ethyl 3-(2-(1-aminocyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylate | C17H21N3O2 | 详情 | 详情 | |
(IVa) | 67769 | (E)-butyl 3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylate | C38H41BrN6O3 | 详情 | 详情 | |
(IVb) | 67768 | (E)-methyl 3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylate | C35H35BrN6O3 | 详情 | 详情 | |
(IVc) | 67767 | (E)-ethyl 3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylate | C36H37BrN6O3 | 详情 | 详情 | |
(I) | 67763 | 2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxylic acid | C19H18BrN3O2 | 详情 | 详情 | |
(II) | 67764 | (E)-butyl 3-(2-(1-aminocyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylate dihydrochloride | C19H25N3O2.2HCl | 详情 | 详情 | |
(V) | 67770 | (E)-3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid | C34H33BrN6O3 | 详情 | 详情 |